GILD · News · 20260819N

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-08-19 · Importance 47 · Surprise 22

Gilead Sciences reported quarterly revenue of approximately $7.8 billion for the second quarter of 2026. Revenue increased 10.6% year over year, exceeding the materiality threshold and indicating strong annual growth. Third-party reporting attributed investor support to strong performance in Gilead’s HIV portfolio, although no segment-level dollar breakdown or sequential comparison was provided.

Key facts